Figure 4.

In vivo viral replication and oncolytic effect of FUVAC

(A) Schedule of MDRVV or FUVAC treatment against the bilateral CT26 tumor model. CT26 cells were bilaterally transplanted on BALB/c mice through subcutaneous injection. When the average tumor volume reached 60 mm³, 5 × 10⁷ PFUs of MDRVV or FUVAC-Luc/LacZ were intratumorally injected three times every 2 days. (B) In vivo bioluminescence imaging of the viral replication. Viral Fluc luminescence was detected by VivoGlo Luciferin (3 mg/mouse; Promega) on day 3. (C) Quantification of the viral luminescence on days 1, 3, 5, and 7 after the first virus injection. Fluc signals were separately quantified in the injection and non-injection sites. Mean luminescence (ph/s) ± SEM are shown. ∗p < 0.05 (two-way ANOVA). (D) Tumor growth was separately monitored in the injection and non-injection sites. Results are representative of two independent experiments comprising 6–8 mice/group (n = 12, 14, or 15 for PBS, MDRVV, or FUVAC, respectively). Mean tumor volume (mm³) ± SEM are shown. ∗∗p < 0.01, ∗∗∗p < 0.001 (two-way ANOVA).